April 12, 2019 06:27 AM EDTUpdated May 30, 12:08 PM
R&D
Pharma

A block­buster cock­tail? Gilead slides No­vo Nordisk's semaglu­tide in­to new NASH triple ther­a­py

Amber Tong

In case you didn’t get the memo, Gilead is bet­ting that a cock­tail ap­proach will win them a cov­et­ed place in the NASH show­down. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Ver­sant un­veils Light Horse with $62M and a part­ner­ship with No­var­tis

Af­ter lack­lus­ter 2024, bio­phar­ma in­dus­try prays stalled M&A will fi­nal­ly move in­to gear

IGM Bio­sciences’ au­toim­mune piv­ot lasts three months af­ter in­ter­im da­ta dis­ap­point

Aio­los team re­unites with $411M for new biotech with obe­si­ty drugs from Chi­na

Ex­clu­sive: First-of-its-kind in­fant DNA ed­it leads to ap­par­ent cure in dis­ease that set back field 25 years ago

Shore­line cuts staff as its part­ner­ship with Gilead­'s Kite is now in flux

A service from the Financial Times